晚期脑膜瘤患者动脉内给予肽受体放射性核素治疗的初步安全性与疗效
本研究评估了晚期进展性脑膜瘤患者经动脉内给予[177Lu]Lu-HA-DOTATATE肽受体放射性核素治疗(PRRT)的安全性与疗效。13例患者接受1-4个周期(中位4周期)动脉内PRRT,治疗耐受良好,主要为1-2级血液学毒性;13例中10例达影像学疾病控制,9例临床症状控制良好。作者认为动脉内PRRT可行且安全,可能较静脉PRRT改善影像学和临床疾病控制。
要点
- 13例晚期进展性脑膜瘤患者接受动脉内[177Lu]Lu-HA-DOTATATE PRRT,中位4周期
- 治疗耐受良好,毒性主要为1-2级血液学毒性
- 13例中10例影像学疾病控制,9例临床症状控制良好
核心结论
- 晚期脑膜瘤患者动脉内PRRT可行且安全。
- 动脉内PRRT可能较静脉PRRT改善影像学和临床疾病控制。
- 作者认为高度有必要开展进一步研究以验证这些初步发现并探究长期结局。
研究设计与样本
- 研究纳入13例晚期进展性脑膜瘤患者(8例女性、5例男性;平均年龄65±13岁),接受动脉内[177Lu]Lu-HA-DOTATATE PRRT,共1-4个周期(中位4个周期),每周期平均活度7,428±237 MBq(范围6,000-7,700 MBq)。
- 安全性按不良事件通用术语标准5.0版评估,治疗反应按所提出的脑膜瘤神经肿瘤学反应评估标准及生长抑素受体导向PET/CT评估。
主要发现
- 治疗耐受良好,毒性主要为1-2级血液学毒性。
- 13例患者中10例在治疗后随访时显示影像学疾病控制(其中1例完全缓解、1例部分缓解、8例疾病稳定)。
- 13例患者中9例显示临床症状控制良好。
局限性
- 作者认为高度有必要开展进一步研究以验证这些初步发现并探究长期结局。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Peptide receptor radionuclide therapy (PRRT) is a treatment option for patients with advanced meningioma. Recently, intraarterial application of the radiolabeled somatostatin receptor agonists has been introduced as an alternative to standard intravenous administration. In this study, we assessed the safety and efficacy of intraarterial PRRT in patients with advanced, progressive meningioma. Methods: Patients with advanced, progressive meningioma underwent intraarterial PRRT with [177Lu]Lu-HA-DOTATATE. The safety of PRRT was evaluated according to the Common Terminology Criteria for Adverse Events version 5.0. Treatment response was assessed according to the proposed Response Assessment in Neuro-Oncology criteria for meningiomas and somatostatin receptor-directed PET/CT. Results: Thirteen patients (8 women, 5 men; mean age, 65 ± 13 y) with advanced meningioma underwent 1-4 cycles (median, 4 cycles) of intraarterial PRRT with [177Lu]Lu-HA-DOTATATE (mean activity per cycle, 7,428 ± 237 MBq; range, 6,000-7,700 MBq). Treatment was well tolerated with mainly grade 1-2 hematologic toxicity. Ten of 13 patients showed radiologic disease control at follow-up after therapy (1/10 complete remission, 1/10 partial remission, 8/10 stable disease), and 9 of 13 patients showed good control of clinical symptoms. Conclusion: Intraarterial PRRT in patients with advanced meningioma is feasible and safe. It may result in improved radiologic and clinical disease control compared with intravenous PRRT. Further research to validate these initial findings and to investigate long-term outcomes is highly warranted.
引用
- Amerein A, Maurer C, Kircher M, et al. Intraarterial Administration of Peptide Receptor Radionuclide Therapy in Patients with Advanced Meningioma: Initial Safety and Efficacy. J Nucl Med. 2024. PMID: 39448269. doi:10.2967/jnumed.124.268217
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。